Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a dy
Why Is Acadia (ACAD) Up 22.6% Since Last Earnings Report?
12:31pm, Friday, 05'th Dec 2025
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Fisher Asset Management LLC Sells 44,710 Shares of ACADIA Pharmaceuticals Inc. $ACAD
04:52am, Friday, 05'th Dec 2025
Fisher Asset Management LLC decreased its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 12.6% in the second quarter, according to the company in its most recent 13F filing with t
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality
06:26pm, Thursday, 04'th Dec 2025
Acadia Pharmaceuticals Inc. is rated Buy for its steady NUPLAZID/DAYBUE franchises and pipeline-driven upside potential. NUPLAZID's patent protection now extends to 2030, supporting >10% Y/Y revenue g
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?
07:12pm, Wednesday, 03'rd Dec 2025
Connecticut-based fund Braidwell bought 2,378,655 shares of Acadia Pharmaceuticals in the third quarter, representing a new position valued at about $50.8 million as of September 30. The transaction r
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
01:23pm, Tuesday, 02'nd Dec 2025
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
10:51am, Friday, 28'th Nov 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
04:05pm, Thursday, 20'th Nov 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citi's 2025 Global Healthcare Conference on Tuesday, December 2, 2
Envestnet Asset Management Inc. Raises Holdings in ACADIA Pharmaceuticals Inc. $ACAD
04:23am, Sunday, 16'th Nov 2025
Envestnet Asset Management Inc. increased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 14.0% during the undefined quarter, according to the company in its most recent Form 13F
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
10:51am, Wednesday, 12'th Nov 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Atria Investments Inc Boosts Holdings in ACADIA Pharmaceuticals Inc. $ACAD
04:52am, Tuesday, 11'th Nov 2025
Atria Investments Inc boosted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 26.1% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fi
ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript
04:31pm, Monday, 10'th Nov 2025
ACADIA Pharmaceuticals Inc. ( ACAD ) UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM EST Company Participants Mark Schneyer - Executive VP & CFO Ponni Subbiah Conference Call Participa
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
12:26pm, Thursday, 06'th Nov 2025
Acadia's third-quarter earnings and revenues top forecasts as Nuplazid and Daybue sales power double-digit annual growth.
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript
04:36am, Thursday, 06'th Nov 2025
ACADIA Pharmaceuticals Inc. ( ACAD ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Albert Kildani Catherine Owen Adams - CEO & Director Thomas Garner - Executive VP & Chief C
Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates
06:20pm, Wednesday, 05'th Nov 2025
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.2 per share a year ago.
